August 16, 2023

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/ Madam,

Sub: Press Release - Aurobindo to launch HIV triple combination product for children living with HIV in low- and middle-income countries under voluntary licence from ViiV Healthcare.

We enclose a copy of the Press Release that is being issued by the Company in connection with launch of HIV triple combination product for children living with HIV in low- and middle-income countries under voluntary licence from ViiV Healthcare; first generic to get USFDA tentative approval for a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine dolutegravir and lamivudine.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

ADIREDDY BADDIGAM
Digitally signed by ADIREDDY BADDIGAM
Date: 2023.08.16 18:53:57 +05'30'

B. Adi Reddy
Company Secretary

Encl: as above

Hyderabad, India, 16th August 2023

Aurobindo to launch HIV triple combination product for children living with HIV in low- and middle-income countries under voluntary licence from ViiV Healthcare; first generic to get USFDA tentative approval for a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine

Aurobindo Pharma Limited (along with its subsidiaries together referred to as "Aurobindo") is pleased to announce USFDA tentative approval under the PEPFAR program for the first generic dispersible tablet formulation of the fixed dose combination Abacavir 60mg + Lamivudine 30 mg + Dolutegravir 5 mg (pALD), for the treatment of children living with HIV weighing 6 kg to <25 kg and aged at least 3 months. Aurobindo has a paediatric dolutegravir voluntary licence with ViiV Healthcare, enabling development and supply of this product in 123 Low and Middle-Income Countries (LMIC), including India. This is one of the fastest approvals for a generic combination product following approval of the innovator formulation, with ViiV having secured USFDA approval in March 2022. Aurobindo's product is already filed with the Drugs Controller General of India (DCGI) and is expected to be approved soon.

The dispersible fixed dose combination of abacavir, dolutegravir and lamivudine is identified by the WHO as a priority ART option for children living with HIV, and this generic approval will help to enable broad and affordable supply in low- and middle-income countries. Aurobindo has capacities in their FDA approved plant to meet the market demand for this product and commercial production will commence in Q3 FY24.

Mr. K. Nithyananda Reddy, Vice Chairman & Managing Director, Aurobindo said, "We are extremely glad that with this approval, more than a million children could benefit from this product thereby helping to increase the treatment coverage of children in 123 countries. It will be our endeavor to make this product accessible as soon as possible. This has become a reality today by the excellent collaborative partnership between ViiV Healthcare, CHAI, Unitaid and Aurobindo."

Helen McDowell, Head of Government Affairs & Global Public Health, ViiV Healthcare, said, "ViiV is proud to have partnered with CHAI, Unitaid and Aurobindo over the last three years to accelerate the development and availability of generic age-appropriate HIV treatment in resource-limited settings. Today's news is an important step forward in ensuring children living with HIV can access appropriate care and reinforces our commitment to leave no person living with HIV behind."

About Paediatric Abacavir 60mg+Lamivudine 30mg+Dolutegravir 5mg) dispersible tablets

pALD dispersible tablet formulation of the fixed dose combination of *abacavir*, *dolutegravir* and *lamivudine* for the treatment of paediatric patients weighing 6 kg to <25 kg with human immunodeficiency virus type 1 (HIV-1) to be administered by dissolving in water, strawberry cream flavour, once a day. The number of tablets administered is based on weight of the child as prescribed by the physician. Available pack size is 180's, for multi-month dispensing.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012. The company's aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

To know more, please log on to www.aurobindo.com

For further information or queries, please contact:

Soumen Biswas | Deepti Thakur
Investor Relations | Corporate Communications
Phone: +91 40 66725401 / 66725000
Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

ADIREDDY BADDIGAM
Digitally signed by ADIREDDY BADDIGAM
Date: 2023.08.16 18:54:30 +05'30'
PAN No. AABCA7366H